Has GSK (GSK) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

A month after the FDA lifted its clinical hold on GSK’s vaginal yeast infection drug Brexafemme (ibrexafungerp), the developer of the treatment, Scynexis, has resumed a phase 3 study in another use.

British drugmaker GSK is preparing for potential new U.S. tariffs on its medicines and can handle the challenge, the company’s leader said Wednesday. “I would say we’ve been preparing ...

GSK Plc halted a trial following positive results for an oral antibiotic to treat complicated urinary tract infections that could replace an intravenous medicine that is typically used. The ...

After years of picking up royalties on GSK’s asthma and COPD inhaler Trelegy, Theravance Biopharma is opting to sell its remaining financial interest to GSK in exchange for a cash reward of $225 ...

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem ...

GSK already scores pretty well among the top 14 pharma companies when it comes to R&D efficiency – ranking third behind Pfizer and Novartis in an analysis of R&D productivity published last year ...

GSK just hit one of its main objectives for 2025 after getting FDA approval of anti-IL-5 antibody Nucala as a treatment for chronic obstructive pulmonary disease (COPD). Nucala (mepolizumab) has ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...